INOTIV INC. - COMMON

Kenneth Swart, Ph.D., Joins Inotiv as Vice President, Bioanalytical Sciences to Drive Growth of Expanding Laboratory Solutions Offerings

11 May 2021 15:05:00 By Nasdaq GlobeNewswire

Inotiv, Inc. Announces Second Quarter Fiscal 2021 Financial Results

05 May 2021 15:05:01 By Nasdaq GlobeNewswire

Inotiv, Inc. Announces Debt Financing and Completion of Acquisitions of HistoTox Labs, Inc. and Bolder BioPATH, Inc.

30 Apr 2021 14:40:00 By Nasdaq GlobeNewswire

Inotiv, Inc. to Report Second Quarter Fiscal 2021 Financial Results and Host Conference Call on Wednesday, May 5, 2021

26 Apr 2021 07:33:00 By Nasdaq GlobeNewswire

Inotiv, Inc. Announces Closing of Public Offering and Full Exercise of Underwriter’s Option to Purchase Additional Shares

23 Apr 2021 10:15:00 By Nasdaq GlobeNewswire

Inotiv, Inc. Announces Pricing of Public Offering of 2,647,059 Common Shares

21 Apr 2021 05:05:00 By Nasdaq GlobeNewswire

Inotiv, Inc. Announces Proposed Public Offering of Common Shares

20 Apr 2021 16:16:00 By Nasdaq GlobeNewswire

Inotiv, Inc. Announces Select Preliminary Unaudited Financial Results for Second Quarter and Year to Date Fiscal 2021

20 Apr 2021 16:12:42 By Nasdaq GlobeNewswire

Inotiv, Inc. Announces Plan to Expand the Company’s Internal Operations

19 Apr 2021 06:00:00 By Nasdaq GlobeNewswire

Inotiv, Inc. Announces Expansion of Pharmacology and Pathology Offerings with Agreement to Purchase Bolder BioPATH, Inc.

16 Apr 2021 07:33:00 By Nasdaq GlobeNewswire

Inotiv, Inc. Enhances Histopathology Offering with Announcement of Agreement to Purchase HistoTox Labs, Inc.

13 Apr 2021 15:35:00 By Nasdaq GlobeNewswire

Inotiv, Inc. Announces Partnership with PhoenixBio Co., Ltd. to Expand Discovery Pharmacology Offering

06 Apr 2021 07:33:00 By Nasdaq GlobeNewswire